Posted by Michael Wonder on 07 Aug 2023
Viatris and Mapi Pharma announce FDA acceptance of new drug application filing for glatiramer acetate depot for the treatment of relapsing forms of multiple sclerosis
7 August 2023 - FDA assigns PDUFA target action date of 8 March 2024.
wire/ -- Viatris and Mapi Pharma today announced that the US FDA has accepted for review the companies' recently submitted new drug application for glatiramer acetate depot 40 mg.
